About Andrea Robles

Articles by Andrea Robles

Por Qué es Importante Estudiar las Etnias en el Mieloma: la Mutación IRF4 y los Resultados de los Pacientes Hispanos
Mar 11, 2024
ASH 2023: Prognostic significance of Malnutrition and sarcopenia in older adults with AML.
Feb 21, 2024
The Innovation of Myeloma in the 2020s and Beyond
Sep 20, 2023
ASCO 2023: Comparing BLENREP (belantamab-mafodotin) to POMALYST (pomalidomide) and dex
Jun 08, 2023
Why Studying Ethnicities in Myeloma is Important: The IRF4 Mutation and Hispanic Patient Outcomes
May 02, 2023
$Clinical Trial: A Four-Drug Combination Using Isatuximab for Relapsed/Refractory Multiple Myeloma image$

Clinical Trial: A Four-Drug Combination Using Isatuximab for Relapsed/Refractory Multiple Myeloma
Apr 13, 2023
Clinical Trial: Predictors of Progression to Myeloma in Patients With MGUS or SMM at MD Anderson
Oct 13, 2022
AML Round Table: What's Next if You Relapse?
Oct 04, 2022
Myeloma Round Table: Deep Insights Into Big Issues in Myeloma — Miami, May 21, 2022 (Part 1)
Aug 21, 2022
Myeloma Round Table: Developing a Treatment Strategy — Chicago, April 30, 2022 (Part 2)
Aug 15, 2022
Myeloma Round Table: Essential Information for Newly Diagnosed Patients — Chicago, April 30, 2022 (Part 1)
Aug 10, 2022
$Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston, March 26, 2022 (Part 2) image$

Myeloma Round Table: Treating Relapsed/Refractory Disease at MD Anderson — Houston, March 26, 2022 (Part 2)
Aug 08, 2022
The Difference Between 1Q Gain and 1Q Amplification in Multiple Myeloma
Jul 14, 2022